Business Daily Media

The Times Real Estate

.

IonOpticks' Custom Chromatography Column to Become Biognosys' Standard for High-Quality Proteomic Insights

  • Written by PR Newswire

MELBOURNE, Australia and ZURICH, Dec. 6, 2024 /PRNewswire/ -- Today, IonOpticks, a world leading provider of chromatography solutions, and Biognosys, a global leader in mass spectrometry-based proteomics contract research services, announce a long-term supply agreement. Under the agreement, IonOpticks will supply Biognosys with custom chromatography columns to support the standardisation of its research services platforms and enable deeper, reproducible proteome profiling.  

Following extensive consultation with the Biognosys team, IonOpticks has developed a custom chromatography column, which is tailored to Biognosys' needs and is available exclusively for use in their TrueDiscovery®, TrueSignature®, and TrueTarget® contract research services.

Consistent with IonOpticks' dedication to high-quality, tailored solutions, the custom column integrates seamlessly into Biognosys' workflows, addressing the company's unwavering criteria for chromatography that maximises sensitivity, depth of coverage and reproducibility in the context of their broader platform.

"Collaborating with the world-class team at Biognosys has been an incredibly rewarding experience. Developing a column that stands up to their rigorous performance and quality standards has been an exciting project, aligning well with our broader ambition to continue delivering the best performing columns to meet the expanding needs of the market," says Xavier Perronnet, CEO of IonOpticks.

"This partnership is consistent with our mission to work with the best, to develop columns that enable users to push the boundaries of proteomics research, whilst making LC-MS workflows for proteomics more accessible. Biognosys' services are outstanding, and their offerings are extremely valuable to a diverse client base.  We're delighted to be contributing our expertise in chromatography to their overall offering," Perronnet continues.

"At Biognosys, our priority is to provide the best research services available to a broad array of biotech and pharma customers, requiring scrutiny of every aspect of our platforms to ensure they operate at their peak. Chromatographic performance, the separation of biological analytes prior to detection, is a critical factor for the success of LC-MS workflows and directly impacts discovery outcomes. We were keen to collaborate with the IonOpticks team to develop a chromatography column specifically tailored to our specific requirements, and they delivered," says Lukas Reiter, Ph.D., Chief Technology Officer at Biognosys.

IonOpticks and Biognosys are proud to collaborate and set new benchmarks in LC-MS-based research, reaffirming their commitment to delivering high-performance solutions that drive innovation and shape the future of proteomics.

--- ENDS ---

About IonOpticks IonOpticks produces high-performance chromatography solutions for the global research community enhancing mass spectrometry (LC-MS) and high-end proteomics research. Their solutions enhance the sensitivity of mass spectrometry sample analysis, enabling scientists and clinicians to discover more from their samples. These advancements are valuable for a broad range of applications within the field of biological and medical research including drug discovery, phosphoproteomics and shotgun proteomics.

https://ionopticks.com/[1]

About Biognosys 

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery®, TrueTarget®, and TrueSignature® research service platforms, our flagship software Spectronaut®, and the PQ500™ kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible.

For more information, visit biognosys.com[2].

 

References

  1. ^ https://ionopticks.com/ (ionopticks.com)
  2. ^ biognosys.com (biognosys.com)

Read more https://www.prnasia.com/story/archive/4571614_AE71614_0

Five signs that AI is growing faster than the internet did

What do Aussie businesses need to do to keep up? There has been mounting chatter that AI is growing even faster than the rapid acceleration we sa...

Protecting Your Small Business from Cyber Threats This Holiday Season

The holiday season brings a surge of online activity for small and medium businesses (SMBs), with increased sales and customer inquiries offering ...

Essential SEO Strategies: Boosting Your Real Estate Business

In recent years, it is said that more and more people are searching for properties online than those who visit real estate companies in person. For ...

Every Business Needs to Apply a Concrete Strategy

Do you want your website to rank higher in the top results of the Google search engine? Then hire the excellent SEO Services in Australia for your n...

Navigating Cyber Fraud After a Natural Disaster

As Australia enters another long, hot and potentially destructive summer, businesses and residents are preparing for the natural disasters synonym...

8seats messaging startup aims to transform business communication

The new platform brings an innovative approach to unite office-based and desk-less teams 8seats, a next-generation messaging platform for busine...

Sell by LayBy